Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma

Hepatol Int. 2023 Aug;17(4):827-829. doi: 10.1007/s12072-023-10533-w. Epub 2023 May 15.

Authors

Shuichiro Shiina¹, Hitoshi Maruyama², Maki Tobari², Tatsuya Yamashita³

Affiliations

¹ Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan. s.shiina@gmail.com.
² Department of Gastroenterology, Juntendo University, 2-1-1, Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan.
³ Department of Gastroenterology, Kanazawa University, 13-1 Takara-Machi, Kanazawa, Ishikawa, Japan.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / therapy
Humans
Immunotherapy / adverse effects
Liver Neoplasms* / pathology
Liver Neoplasms* / therapy
Non-alcoholic Fatty Liver Disease* / pathology
Non-alcoholic Fatty Liver Disease* / therapy
Obesity / complications
Obesity / therapy